These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Tumor resistance to CD8+ T cell-based therapeutic vaccination. Huang Y; Shah S; Qiao L Arch Immunol Ther Exp (Warsz); 2007; 55(4):205-17. PubMed ID: 17659376 [TBL] [Abstract][Full Text] [Related]
5. Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Wein LM; Wu JT; Kirn DH Cancer Res; 2003 Mar; 63(6):1317-24. PubMed ID: 12649193 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic immune response induced by intratumoral expression of the fusogenic membrane protein of vesicular stomatitis virus and cytokines encoded by adenoviral vectors. Hoffmann D; Bayer W; Wildner O Int J Mol Med; 2007 Nov; 20(5):673-81. PubMed ID: 17912460 [TBL] [Abstract][Full Text] [Related]
7. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma. Nakano H; Kishida T; Asada H; Shin-Ya M; Shinomiya T; Imanishi J; Shimada T; Nakai S; Takeuchi M; Hisa Y; Mazda O J Gene Med; 2006 Jan; 8(1):90-9. PubMed ID: 16097036 [TBL] [Abstract][Full Text] [Related]
8. Reovirus - possible therapy of cancer. Figova K; Hrabeta J; Eckschlager T Neoplasma; 2006; 53(6):457-62. PubMed ID: 17167712 [TBL] [Abstract][Full Text] [Related]
9. Multi-stability and multi-instability phenomena in a mathematical model of tumor-immune-virus interactions. Eftimie R; Dushoff J; Bridle BW; Bramson JL; Earn DJ Bull Math Biol; 2011 Dec; 73(12):2932-61. PubMed ID: 21476110 [TBL] [Abstract][Full Text] [Related]
10. [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy]. Benchetrit F; Gazagne A; Adotevi O; Haicheur N; Godard B; Badoual C; Fridman WH; Tartour E Bull Cancer; 2003; 90(8-9):677-85. PubMed ID: 14609756 [TBL] [Abstract][Full Text] [Related]
11. In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154. Loskog A; Tötterman TH; Böhle A; Brandau S Cancer Gene Ther; 2002 Oct; 9(10):846-53. PubMed ID: 12224026 [TBL] [Abstract][Full Text] [Related]
12. Sequence variation in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes. Rimmelzwaan GF; Boon AC; Voeten JT; Berkhoff EG; Fouchier RA; Osterhaus AD Virus Res; 2004 Jul; 103(1-2):97-100. PubMed ID: 15163496 [TBL] [Abstract][Full Text] [Related]
13. Transfer of in vitro expanded T lymphocytes after activation with dendritomas prolonged survival of mice challenged with EL4 tumor cells. Li J; Theofanous L; Stickel S; Bouton-Verville H; Burgin KE; Jakubchak S; Wagner TE; Wei Y Int J Oncol; 2007 Jul; 31(1):193-7. PubMed ID: 17549421 [TBL] [Abstract][Full Text] [Related]
14. Impact of antigen expression kinetics on the effectiveness of HIV-specific cytotoxic T lymphocytes. van Baalen CA; Guillon C; van Baalen M; Verschuren EJ; Boers PH; Osterhaus AD; Gruters RA Eur J Immunol; 2002 Sep; 32(9):2644-52. PubMed ID: 12207349 [TBL] [Abstract][Full Text] [Related]
15. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Wakimoto H; Johnson PR; Knipe DM; Chiocca EA Gene Ther; 2003 Jun; 10(11):983-90. PubMed ID: 12756419 [TBL] [Abstract][Full Text] [Related]
16. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors. Bioley G; Guillaume P; Luescher I; Bhardwaj N; Mears G; Old L; Valmori D; Ayyoub M J Immunother; 2009; 32(2):161-8. PubMed ID: 19238015 [TBL] [Abstract][Full Text] [Related]
17. [An experiment study of in vitro induced antitumor immune responses by vaccination of tumor lysate-pulsed dendritic cells to kill SO-RB(50)]. Tang S; Li YP; Ying FW; Li YQ; Feng GG; Yi YZ Zhonghua Yan Ke Za Zhi; 2004 Apr; 40(4):229-33. PubMed ID: 15268828 [TBL] [Abstract][Full Text] [Related]
18. [Treatment of hepatocellular carcinoma with a novel gene-viral therapeutic system CNHK300-murine endostatin]. Li GC; Nie MM; Yang JM; Su CQ; Sun LC; Qian YZ; Sham J; Fang GE; Wu MC; Qian QJ Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):943-8. PubMed ID: 15329284 [TBL] [Abstract][Full Text] [Related]
19. Potent tumor-specific immunity induced by an in vivo heat shock protein-suicide gene-based tumor vaccine. Ren W; Strube R; Zhang X; Chen SY; Huang XF Cancer Res; 2004 Sep; 64(18):6645-51. PubMed ID: 15374979 [TBL] [Abstract][Full Text] [Related]